替吉奥胶囊在晚期大肠癌患者维持治疗中的临床观察
| 作者: |
1蒋丽媛,
1李华,
1井磊,
1赵磬,
1赵彩霞
1 保定市第一医院肿瘤内科，河北 保定 071000 |
| 通讯: |
李华
Email: 982469544@qq.com |
| DOI: | 10.3978/j.issn.2095-6959.2016.04.009 |
摘要
目的：观察替吉奥在晚期大肠癌(结直肠癌)患者维持治疗的疗效和不良反应。方法：38例确诊为晚期大肠癌的患者，经过氟尿嘧啶类组成的联合化疗方案化疗4~6周期，化疗后部分缓解(partial response，PR)或疾病稳定(stable disease，SD)的患者，被分为治疗组和观察组。治疗组采用替吉奥单药口服维持治疗，连用2周，停药1周，3周为一个周期。观察组不予任何治疗。每2周期后行影像学检查评价疗效、不良反应及随访情况。结果：治疗组总有效率为45.5%，临床受益率为81.8%，中位无疾病进展时间为5.7个月，中位总生存期为10.9个月；观察组总有效率为31.3%，临床受益率为68.8%，中位无疾病进展时间为3.1个月，中位总生存期为6.7个月；两组近期疗效、中位无疾病进展时间及中位生存期比较差异有统计学意义(P<0.05)。毒副反应主要为Ⅰ~Ⅲ度骨髓抑制、消化道反应、肝功能损伤及手足综合症。结论：替吉奥在晚期大肠癌患者维持治疗中效果肯定、生存质量高、毒副作用小。
关键词：
替吉奥
晚期
大肠癌
维持治疗
疗效
毒副作用
Clinical observation of S-1 in the maintenance therapy of patients with advanced colorectal cancer
CorrespondingAuthor: LI Hua Email: 982469544@qq.com
DOI: 10.3978/j.issn.2095-6959.2016.04.009
Abstract
Objective: To evaluate the clinical efficacy, the clinical benefit response and adverse reaction of S-1 in the maintenance therapy of patients with advanced colorectal cancer (colon cancer and rectal cancer). Methods: Thirty-eight patients with advanced colorectal cancer who underwent combined chemotherapy of fluorouracil in 4~6 cycles. The partial response (PR) or stable disease (SD) patients were divided into S-1 group and observation group after chemotherapy. For the S-1 group, 3 weeks constituted a cycle. Among the cycle, taking 2 weeks for S-1, 1 week of stopping medication. In the observation group, no treatment was performed. After two consecutive treatment circles, the clinical efficacy, adverse effects and follow-up condition were evaluated. Results: The total response rate of S-1 group was 45.5% and 31.3% of the observation group and the progress free survival (PFS) were 5.7 and
3.1 months respectively. The clinical benefit response of S-1 group was 81.8% and 68.8% of the observation group and the MST were 10.9 and 6.7 months respectively. There was significant difference between the two groups (P<0.05). The major adverse events were myelosuppression ranging from grade I to III, disgusting damage of liver function and hand-foot syndrome. Conclusion: The S-1 shows positive effect for patients with advanced colorectal cancer in the maintenance therapy. It can achieve a better quality of life and small side effects for the patients.
3.1 months respectively. The clinical benefit response of S-1 group was 81.8% and 68.8% of the observation group and the MST were 10.9 and 6.7 months respectively. There was significant difference between the two groups (P<0.05). The major adverse events were myelosuppression ranging from grade I to III, disgusting damage of liver function and hand-foot syndrome. Conclusion: The S-1 shows positive effect for patients with advanced colorectal cancer in the maintenance therapy. It can achieve a better quality of life and small side effects for the patients.